MedicalResearch.com Interview with: Emilie Jouanjus, PharmD, PhD
Risques, maladies chroniques et handicaps
Facult_e de M_edecine,
Guesde, Toulouse 31073, France.
MedicalResearch.com: What are the main findings of the study?Dr. Jouanjus: Our study emphasizes that cardiovascular complications make up 1.8 percent of cannabis-related health complications reported in France. These were cases of peripheral arteriopathies, and cardiac and cerebrovascular disorders, some of which resulted in the death. These findings conducted us to conclude that marijuana is a possible risk factor for cardiovascular disease in young adults.
(more…)
MedicalResearch.com Interview with: Mary-Ann Fitzcharles, MB, ChB, MRCP(UK), FRCP(C)
McGill University Health Centre
Division of Rheumatology and Alan Edwards Pain Management Unit
MedicalResearch.com: What are the highlights of your review?Dr. Fitzcharles: Thank you for your interest in the review article which will shortly be published in Arthritis Care & Research. This was not a research study but rather a review focused towards the use of herbal cannabis for patients with rheumatic diseases.
The essence of our message after a thorough review of the literature is that there is not a single study published regarding efficacy or side effects of herbal cannabis in the rheumatic diseases. It is notable that almost 2 thirds of persons using herbal cannabis for therapeutic reasons report use for musculoskeletal complaints. In the 21st century, we cannot rely upon heresay or anecdote to justify use of a treatment intervention. It is unacceptable to recommend use of a substance without knowledge of concentration of molecules in the product, any knowledge of blood concentrations that might have a positive or negative effect, and formal study in defined patient populations with acceptable endpoint criteria and evidence for short and long term risks.
(more…)
MedicalResearch.com Interview with: Joanne E. Brady SM
Senior Staff Associate
Department of Anesthesiology
Doctoral Candidate in Epidemiology
Columbia University Medical Center
New York, NY 10032
Department of Epidemiology,
Columbia’s Mailman School of Public HealthMedicalResearch.com: What are the main findings of the study?Answer:The prevalence of non-alcohol drugs detected in fatally injured drivers in the U.S. increased from 17% in 1999 to 28% in 2010. The increases are largely driven by the tripling in the prevalence of cannabis.
(more…)
MedicalResearch.com Interview with: David J. Allsop, PhD
National Cannabis Prevention and Information Centre, National Drug and Alcohol Research Centre, Faculty of Medicine
Now with the School of Psychology, University of Sydney, Sydney, Australia
MedicalResearch.com: What are the main findings of the study?Dr. Allsop: We found that administering a botanical preparation of the cannabinoids Tetrahydrocannabidiol (THC - the main psychoactive ingredient in cannabis) and Cannabidiol (a lesser known component of the cannabis plant that
counteracts the psychotogenic effects of THC with anxiolytic properties) to
dependent cannabis smokers during initial abstinence from cannabis
substantially dampened their withdrawal experience. In essence this is akin
to Nicotine Replacement Therapy (NRT) but for cannabis users. It might seem
obvious - sure you give cannabis users a cannabis preparation and they find
it easier to quit - but this is important because it has never been done
before - and we currently have no consensus evidence based medicines to
offer cannabis users who ask for help.
(more…)
MedicalResearch.com Interview with:Dr. Matthew J. Smith PhD
Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, 710 N. Lake Shore Drive, 13th Floor, Abbott Hall, Chicago, IL 60611
MedicalResearch.com: What are the main findings of the study?Dr. Smith:We observed that the shapes of brain structures involved in a working memory brain circuit seemed to collapse inward in a similar fashion among both of the groups that had a history of daily cannabis use. These cannabis-related changes in shape were directly related to the participants’ poor performance on working memory tasks. Some of the shape abnormalities were more severe in the group with schizophrenia and the history of daily cannabis use. We also found that participants with an earlier age of daily cannabis use had more abnormal brain shapes.
(more…)
MedicalResearch.com Interview with:W. Scott Burgin, MD
Professor and Chief, Cerebrovascular Division
Director, Comprehensive Stroke Center
Department of Neurology
USF College of Medicine
Tampa General Hospital Stroke Center.
MedicalResearch.com What are the main findings of the study?Dr. Burgin: Two cases of stroke, of embolic appearance, shortly after smoking synthetic marijuana.
(more…)
MedicalResearch.com Interview with:Professor John Zajicek
Professor of Clinical Neuroscience, Centre for Clinical Trials & Health Research - Translational & Stratified Medicine (Peninsula Schools of Medicine and Dentistry)
MedicalResearch.com: What are the main findings of the study?Prof. Zajicek: Our study investigated whether dronabinol (one of the major active ingredients of cannabis) may slow the progression of multiple sclerosis. We currently have no treatments that are effective in modifying the disease course in people with either primary or secondary MS. We did a clinical trial across the UK involving nearly 500 patients, who were randomly allocated to dronabinol or placebo, and followed them up for three years to look at progression on rates. Overall we failed to find an effect of dronabinol on disease progression, either clinically (using a variety of clinical measures) or using magnetic resonance imaging (MRI). There was a suggestion of an effect in people with the least disability (who didn't need a stick to help them walk), and there were no major problems with serious side effects. However, over all the population that took part in the study also progressed less than we expected, which reduced our chances of finding an effect of treatment. The study was not designed to investigate an effect on MS-related symptoms (such as pain and muscle stiffness), which have been investigated before.
(more…)
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.